1169Interim analysis of data from a long-term, extension trial of tafamidis meglumine in patients with transthyretin amyloid cardiomyopathy
Perry Elliott(St Bartholomew's Hospital), Sanjiv J. Shah(Northwestern University), Marla B. Sultan(Pfizer (United States)), Daniel J. Lenihan(Saint Francis Medical Center), Scott L. Hummel(VA Ann Arbor Healthcare System), Brian Drachman(Penn Presbyterian Medical Center), Stephen S. Gottlieb(University of Maryland, Baltimore), Ben Ebede(Pfizer (United States)), Jeffrey H. Schwartz(National Museum of American History), James E. Hoffman(The University of Melbourne), Balarama Gundapaneni(Pfizer (United States))
Cited by 7
Related Papers
ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008
|European Journal of Heart Failure|2008|3.5k
Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases
|European Heart Journal|2013|3.4k
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
|New England Journal of Medicine|2018|2.8k